Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Marina, Ziehn"'
Autor:
Julia Baguña Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue distribution patterns a
Externí odkaz:
https://doaj.org/article/3e65cfb68b9f41b1a866e9a64579ab0e
Autor:
Kristin Galetta, Chinmay Deshpande, Brian C. Healy, Bonnie Glanz, Marina Ziehn, Shrishti Saxena, Anu Paul, Fermisk Saleh, Mikaela Collins, Patricia Gaitan‐Walsh, Paola Castro‐Mendoza, Howard L. Weiner, Tanuja Chitnis
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 631-638 (2021)
Abstract Objective Serum neurofilament light (sNfL) is a promising new biomarker in multiple sclerosis (MS). We explored the relationship between sNfL and health outcomes and resource use in MS patients. Methods MS patients with serum samples and hea
Externí odkaz:
https://doaj.org/article/4b7c25b42f854aa1a018f07ebfcd118e
Autor:
Bernd Kieseier, Bruno Cenni, Barbara Nuesslein-Hildesheim, Enrico Ferrero, Catherine Huck, Denis Eichlisberger, Marina Ziehn
Publikováno v:
Sunday, April 23.
Publikováno v:
Tuesday, April 25.
Autor:
Mitzi Williams, Laura Airas, Tanuja Chitnis, Sarbjit Saini, Michihiro Hide, Gordon Sussman, Jin Nakahara, Robert Bermel, Thomas Dörner, Brett Loop, Marina Ziehn, Roman Willi, Bernd C. Kieseier, Ivan Nikolaev, Sibylle Haemmerle, Artem Zharkov, Richard Siegel, Bruno Cenni, Heinz Wiendl, Marcus Maurer, Ana Giménez-Arnau, Xavier Montalban
Publikováno v:
Tuesday, April 25.
Autor:
Matthew Craner, Yaser Al Malik, Fawzi A. Babtain, Foziah Alshamrani, Mona M. Alkhawajah, Nora Alfugham, Rumaiza H. Al-Yafeai, Salman Aljarallah, Seraj Makkawi, Shireen Qureshi, Marina Ziehn, Hazem Wahba
Publikováno v:
Neurology and therapy. 11(4)
Treatment-pattern data suggest that some patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) may not be receiving optimal treatment. A virtual meeting of ten expert Saudi neurologists, held on October 23, 2020, discussed unmet
Autor:
Fermisk Saleh, Howard L. Weiner, Patricia Gaitan-Walsh, Mikaela Collins, Paola Castro-Mendoza, Anu Paul, Marina Ziehn, Chinmay Deshpande, Shrishti Saxena, Brian C. Healy, Kristin M. Galetta, Bonnie I. Glanz, Tanuja Chitnis
Publikováno v:
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 631-638 (2021)
Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 631-638 (2021)
Objective Serum neurofilament light (sNfL) is a promising new biomarker in multiple sclerosis (MS). We explored the relationship between sNfL and health outcomes and resource use in MS patients. Methods MS patients with serum samples and health‐out
Autor:
Yang, Mao-Draayer, Jeffrey A, Cohen, Amit, Bar-Or, May H, Han, Barry, Singer, Ian M, Williams, Xiangyi, Meng, Chelsea, Elam, Jamie L, Weiss, Gina Mavrikis, Cox, Marina, Ziehn, Bruce Ac, Cree
Publikováno v:
Multiple sclerosis journal - experimental, translational and clinical. 8(3)
Background Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood. Objective Investigate fingolimod's temporal effects on immune cell subsets, and
Autor:
Jeri Burtchell, Daisy Clemmons, Joann Clemmons, Tim Sabutis, Adeline Rosenberg, Jennifer Graves, Michael L. Sweeney, John Kramer, Marina Ziehn, Brandon Brown, Jamie L. Weiss, Ahmed Z. Obeidat
Publikováno v:
Neurology and therapy. 11(3)
The mechanisms of action of disease-modifying therapies (DMTs) for multiple sclerosis (MS) are complex and involve an interplay of immune system components. People with MS (PwMS) may lack a clear understanding of the immunological pathways involved i
Autor:
Jerry S. Wolinsky, Edward Fox, Xiangyi Meng, Marina Ziehn, Ian M. Williams, Bruce A.C. Cree, Fred D. Lublin, Scott Kolodny, Jeffrey A. Cohen
Publikováno v:
Neurology(R) neuroimmunology & neuroinflammation, vol 6, iss 6
Neurology® Neuroimmunology & Neuroinflammation
Neurology® Neuroimmunology & Neuroinflammation
ObjectiveTo evaluate lymphocyte counts and incidences of infections in patients with primary progressive MS (PPMS) receiving fingolimod 0.5 mg/d or placebo over 5 years during the INFORMS study, to assess infection rates with longer-term treatment.Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc6092c18dc1e199d2c251600301b99
https://escholarship.org/uc/item/2vj5x0x9
https://escholarship.org/uc/item/2vj5x0x9